Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Operating expenses:
Research and development	$ 587,240	$ 849,359	$ 1,090,791	$ 1,382,987
Clinical and regulatory	3,373,758	1,113,186	5,543,231	1,959,570
General and administrative	893,242	1,014,888	2,202,398	2,029,758
Total operating expenses	4,854,240	2,977,433	8,836,420	5,372,315
Loss from operations	(4,854,240)	(2,977,433)	(8,836,420)	(5,372,315)
Interest income	20,702	6,546	29,828	17,521
Other income (expense)	3,865	$ 12,530	25,482	$ (26,529)
Interest expense	(73,075)		(148,505)
Total non-operating (expenses) income	(48,508)	$ 19,076	(93,195)	$ (9,008)
Net loss	(4,902,748)	(2,958,357)	(8,929,615)	(5,381,323)
Net loss - non-controlling interest	(189,277)	(111,442)	(306,946)	(203,810)
Net loss attributable to Heat Biologics, Inc.	$ (4,713,471)	$ (2,846,915)	$ (8,622,669)	$ (5,177,513)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted	$ (0.56)	$ (0.44)	$ (1.13)	$ (0.80)
Weighted-average number of common shares used in net loss per share attributable to common stockholders - basic and diluted	8,401,159	6,452,986	7,612,393	6,432,857
Other comprehensive loss:
Net loss	$ (4,902,748)	$ (2,958,357)	$ (8,929,615)	$ (5,381,323)
Unrealized loss on foreign currency translation	(16,185)		(37,051)
Total other comprehensive loss	(4,918,933)	$ (2,958,357)	(8,966,666)	$ (5,381,323)
Comprehensive loss attributable to non-controlling interest	(189,277)	(111,442)	(306,946)	(203,810)
Comprehensive loss	$ (4,729,656)	$ (2,846,915)	$ (8,659,720)	$ (5,177,513)